FDA Designates Pluristem Cell Therapy as Orphan Drug

October 26, 2017

The FDA granted orphan drug designation to Pluristem Therapeutics’ PLX-R18 cell therapy, the company said.

The therapy is intended for the prevention and treatment of acute radiation syndrome, which can result from exposure to nuclear radiation in an attack or accident.

PLX-R18 regenerates damaged bone marrow for the production of blood cells.

View today's stories